Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20,563 result(s) found for: Dose. Displaying page 1 of 1,029.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-001757-40 Sponsor Protocol Number: C3661001 Start Date*: 2021-11-12
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 1/2a DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF 06873600 AS A SINGLE AGENT AND IN COMBINATION WITH EN...
    Medical condition: HR+ HER2- Metastatic Breast Cancer (Part 1 also had Ovarian Cancer and Triple Negative BC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000267-25 Sponsor Protocol Number: STH20412 Start Date*: 2020-03-17
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Characterisation of a novel regimen of very low-dose aspirin combined with rivaroxaban in patients with chronic coronary syndromes: WILL lOWer dose aspirin be better with rivaroxaban in patients wi...
    Medical condition: Chronic coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-002851-41 Sponsor Protocol Number: 1228.1 Start Date*: 2006-03-07
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Reduced factorial design, randomized, double blind trial comparing combinations of telmisartan 20 or 80 mg and simvastatin 20 or 40 mg with single component therapies in the treatment of hypertensi...
    Medical condition: hypertension and dyslipidaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2023-000027-36 Sponsor Protocol Number: DEN-303 Start Date*: 2023-02-03
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Are...
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2022-001146-38 Sponsor Protocol Number: B7471016 Start Date*: 2022-09-27
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS
    Medical condition: Pneumococcal disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005903-11 Sponsor Protocol Number: C4591017 Start Date*: 2022-01-20
    Sponsor Name:BioNTech SE
    Full Title: A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of The Vaccine Candidate BNT162b2 Against COVID-19 i...
    Medical condition: SARS-CoV-2 Infection
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002608-15 Sponsor Protocol Number: CBVS857X2202 Start Date*: 2014-06-12
    Sponsor Name:Novartis Farma SpA
    Full Title: A two-part placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy (SBMA)
    Medical condition: Spinal and bulbar muscular atrophy (SBMA)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10068597 Bulbospinal muscular atrophy congenital PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002014-14 Sponsor Protocol Number: COV-PBO-MO28 Start Date*: 2021-04-20
    Sponsor Name:Fakultní nemocnice Hradec Králové
    Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001762-42 Sponsor Protocol Number: 4658-402 Start Date*: 2020-04-03
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular ...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) SE (Prematurely Ended) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000093-11 Sponsor Protocol Number: 205218 Start Date*: 2017-02-08
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Athe Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningo...
    Medical condition: Healthy volunteers (Infections, Meningococcal)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-006083-11 Sponsor Protocol Number: 110699 to 110704 Start Date*: 2009-03-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccin...
    Medical condition: Adult subjects who received a primary vaccination course with Twinrix Adult following a two-dose schedule or Twinrix Junior following a three-dose schedule as adolescents (12-15 years) approximate...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004445-10 Sponsor Protocol Number: CVAL489K1101 Start Date*: 2016-06-07
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age.
    Medical condition: Hypertension, Chronic Kidney Disease, Nephrotic Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003305-10 Sponsor Protocol Number: B7471011 Start Date*: 2023-02-24
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-004889-35 Sponsor Protocol Number: UCDCRC/21/10 Start Date*: 2021-12-08
    Sponsor Name:University College Dublin
    Full Title: An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a booster mRNA vaccination dose against SARS-Co...
    Medical condition: Severe Acute Respiratory Syndrome Coronavirus 19 (COVID-19/SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NO (Completed) DE (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000281-15 Sponsor Protocol Number: mRNA-1273-P204 Start Date*: 2023-09-19
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and ...
    Medical condition: Coronavirus Disease 2019
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001239-95 Sponsor Protocol Number: TCD17620 Start Date*: 2023-04-25
    Sponsor Name:Sanofi Aventis Recherche & Développement
    Full Title: A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as m...
    Medical condition: Cancer, solid tumor
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004979-14 Sponsor Protocol Number: AR-320-003 Start Date*: 2022-08-18
    Sponsor Name:Aridis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention o...
    Medical condition: Prevention of nosocomial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) BE (Completed) NL (Completed) PT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001008-37 Sponsor Protocol Number: Bab1 Start Date*: 2005-11-01
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006950-30 Sponsor Protocol Number: CLOU064I12201 Start Date*: 2022-08-02
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy
    Medical condition: Allergy, Peanut
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000781-10 Sponsor Protocol Number: STANDLOW Start Date*: 2018-05-31
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: EFFICACY AND TOLERABILITY OF LOW VS. STANDARD DAILY DOSES OF ANTIEPILEPTIC DRUGS IN NEWLY DIAGNOSED, PREVIOUSLY UNTREATED EPILEPSY (STANDLOW). A MULTICENTER, RANDOMIZED, SINGLE-BLIND, PARALLEL GROU...
    Medical condition: EPILEPSY
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10015046 Epilepsy, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:47:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA